News Center - Starna Therapeutics(Suzhou)

11
2026-05

Starry-Pharma Completes Nearly $40 Million Series B+ Financing, Continuing to Deepen Focus on Innovative mRNA Therapies

Starna Therapeutics recently announced the completion of a Series B+ financing round raising nearly $40 million. This round saw participation from a prominent industry fund alongside Hillhouse Ventures, LYFE Capital, Lilly Asia Ventures (LAV), Sherpa Healthcare Partners, Source Code Capital, and Primavera Capital.
17
2025-12

Starna Honors | 2025 China Potential Unicorn Company

On December 13, Great Wall Strategy Consulting released the "China Potential Unicorn Companies Research Report 2025," in which 59 companies from Suzhou Industrial Park were recognized as potential uni
24
2025-10

Starna Therapeutics has secured over 300 million yuan in Series B funding to accelerate the development of its in vivo CAR-T pipeline.

Starna Therapeutics recently announced the completion of a Series B financing round exceeding RMB 300 million. This round was co-led by LYFE Capital, Hillhouse Capital, and Lilly Asia Ventures (LAV),
26
2025-05

The inaugural Wiley Rising Star Scientist Award has been announced! Dr. Qiang Cheng, founder of Starna Therapeutics, is the winner.

On May 24, 2025, the inaugural Wiley Emerging Scientist Award ceremony, hosted by Wiley Publishing, was held in Beijing! This year's award focused on the life sciences field. Following rigorous select
25
2025-04

星锐医药与韩国公司Genexine达成战略合作，推进LNP递送技术在肺部疾病治疗领域的应用

中国苏州，4月25日，韩国生物制药上市企业Genexine (KOSDAQ: 095700)与中国创新药企星锐医药正式达成战略合作，双方将依托前沿的肺靶向LNP递送技术，共同开拓肺部疾病治疗新领域。Suzhou, China, April 25th, 2025, Korean biopharmaceutical company Genexine and China-based innovative

Contact

+86 512 65165336

info@starnatx.com(Investment Cooperation)

Navigation

Platform Pipeline About Us News Center Join Us

Share and follow

Legal Notice | Privacy Policy |